Recall record at a glance
| Official record | F-0822-2023 |
|---|---|
| Category | Food Recalls |
| Classification | Class II |
| FDA record status | Ongoing |
| Recalling firm | FLP LLC |
| Report date | May 17, 2023 |
| Recall initiation date | Mar 29, 2023 |
| Quantity | Lot 1117002 = 5,760 bottles; Lot 0122003 = 1,800 bottles; Lot 0223539 = 180 bottles |
| Location | Tempe, AZ, United States |
Official product description
Dr. Rico Perez Super Kids Colostrum, 60 count chewable tablets dietary supplement, Supplement Facts: 200 mg Colostrum per 1 tablet. HDPE bottle. UPC 8 79840 00044 6. Mfg For: Rico Perez Prod., In2295 Coral Way, Miami, FL 33145.
Why the product was recalled
Colostrum is declared but label does not declare milk.
Distribution information
Distributed in CA, FL, NJ, and NY.
How to read the classification
FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.
Additional record details
Recall type: Voluntary: Firm initiated. Initial notification: Telephone.
What to do next
If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.
About this record
Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.
FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.